<!DOCTYPE html>
<html lang="pt-BR">
  <head>
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="utf-8">
    <title>Problemas no manejo da fibrilação atrial</title>
    <link rel="stylesheet" href="/assets/css/main.css">
    <link rel='shortcut icon' type='image/x-icon' href='/medruas/favicon.ico'/>
  </head>
  <body>
    <div class="nav">
      <span><a href="/">Jardim</a></span> •
      <span><a href="/medruas">MedRuas</a></span> •
      <span><a href="/sobre">Sobre</a></span>
    </div>
    <h1>Problemas no manejo da fibrilação atrial</h1>

    


    <p>O manejo da fibrilação atrial é um assunto que me gera uma certa angustia porque as diretrizes não são muito claras em alguns pontos e existem situações particulares que não existe nenhuma recomendação forte. Em muitos desses casos a orientação é individualizar baseado na experiência e conhecimento do médico  assistente. Entretanto, como prosseguir quando justamente não se tem muita vivência prática e repertório de conduções de casos semelhantes?</p>

<p>Claro que se houver especialistas disponíveis é sempre melhor discutir com eles a melhor conduta, mas nem sempre temos. Então, só resta estudar o que dizem as mais variadas literaturas e tentar traçar o próprio fluxograma, adaptando-o ao longo do tempo. Ao longo desta página vou listar e detalhar alguns desses problemas específicos e discutir sobre o que dizem as literaturas mais renomadas.</p>

<h2 id="anticoagulação-na-cardioversão-da-fa-com-duração-menor-que-48-horas">Anticoagulação na cardioversão da FA com duração menor que 48 horas</h2>

<p><em>Adendo: 48 horas costuma ser o corte padrão mas já existem referências reduzindo esse intervalo para 24 horas com o objetivo de reduzir ainda mais o risco de tromboembolismo, como a nova diretriz da ESC 2024 (o UpToDate também cita que alguns de seus especialistas utilizam o corte de 24 horas e citam o estudo<sup id="fnref:Garg2016"><a href="#fn:Garg2016" class="footnote" rel="footnote" role="doc-noteref">1</a></sup>).</em></p>

<p><strong>É aceito que pacientes que se apresentam com FA de duração definitivamente menor que 48h podem ser cardiovertidos sem a necessidade de pré-anticoagulação</strong> por 3-4 semanas, desde que o seu risco tromboembólico seja baixo (normalmente estimado pelo escore CHA2DS2VASc – ou o CHA2DS2VA) e o ritmo sinusal seja atingido dentro dessas 48 horas. Certo, essa recomendação é até um ponto pacífico, <strong>mas e sobre a anticoagulação pós-cardioversão por pelo menos 4 semanas? Devemos fazer neses pacientes?</strong></p>

<p>O UpToDate diz:</p>
<blockquote>
  <p>If conversion to SR (either spontaneous or via ϲаrԁiοversiοn) occurs within 48 hours of the onset of AF, the thromboembolic risk appears to be very low.<sup id="fnref:Pahng2024"><a href="#fn:Pahng2024" class="footnote" rel="footnote" role="doc-noteref">2</a></sup></p>
</blockquote>

<p>Ainda assim, os autores do UpToDate dizem que preferem anticoagular:</p>

<blockquote>
  <p>For most patients in whom ϲаrԁiοverѕiоn will take place less than 48 hours after the onset of AF, we start a DOAC prior to ϲаrԁiοvеrѕiοո rather than no аոtiϲоаgսlant. […] Of note, the approach presented here is in contrast to the historical approach of some cardiologists proceeding to early ϲаrԁiοverѕiоո without аոtiϲοаgսlаtion if the duration was less than 24 hours. We generally wait at least two to four hours after the first dose of a DOAC to cardiovert.<sup id="fnref:Pahng2024:1"><a href="#fn:Pahng2024" class="footnote" rel="footnote" role="doc-noteref">2</a></sup></p>
</blockquote>

<blockquote>
  <p>No randomized trial has evaluated аոtiϲοаgulаtion compared with no аոtiϲοаgսlatioո in AF patients undergoing ϲаrԁiοvеrѕiοո with a definite duration of ΑF &lt;48 hours. Observational data suggest that the risk of strоkе/thrοmbоеmboliѕm is very low (0  to 0.2 percent) in patients with a definite ΑF duration of &lt;12 hours and a very low stroke risk (CHA2DS2-VASc 0 in men, 1 in women), in whom the benefit of four-week аոtiϲοаgulаtiоn after ϲаrԁiοvеrѕioո is undefined. The 2020 European Society of Cardiology guidelines for the diagnosis and management of ΑF suggest that prescription of аոtiϲοagսlаոts can be optional, based on an individualized approach.<sup id="fnref:Pahng2024:2"><a href="#fn:Pahng2024" class="footnote" rel="footnote" role="doc-noteref">2</a></sup></p>
</blockquote>

<blockquote>
  <p>With regard to the question as to whether to anticoagulate these patients or not, there are no studies comparing hepаrin with no hеpariո in patients with AF of less than 48 hours duration. However, data regarding the rate of clinical thromboembolization after ϲаrԁiοvеrsioո in patients with ΑF of less than 48 hours duration have raised a concern about the safety of ϲаrԁiοverѕiоn without аոtiϲοаgսlаtiоո in this population. In an observational study of 2481 such individuals (5116 successful cardioversions) who were not treated with peri- or postprocedural аոtiϲοagulant, definite thromboembolic events occurred in 38 (0.7 percent) within 30 days (median of two days); of these, 31 were strokes [23]. Four additional patients suffered a transient ischemic attack. Age greater than 60 years, female sex, heart failure, and diabetes were the strongest predictors of embolization, with nearly 10 percent of those with both heart failure and diabetes experiencing a ѕtrоke. The risk of ѕtrоke in those without heart failure and age less than 60 years was 0.2 percent. An observational study of 16,274 patients undergoing electrical ϲаrԁiοvеrѕiоո with and without oral аոtiϲоаgսlаnt therapy also demonstrated that the absence of postcardioversion аոtiϲοаgսlation was associated with a high risk of thrοmbοembοlism, regardless of CHA2DS2-VASc scores [26]. There was a greater-than-twofold increased risk of thrοmbоеmbοlism in those not treated with postcardioversion аոtiϲοаgսlаtiоn (hazard ratio 2.21; 95% CI 0.79-6.77 and 2.40; 95% CI 1.46-3.95 with CHA2DS2-VASc score 0 to 1 and CHA2DS2-VASc score 2 or more, respectively). The rationale for lack of postcardioversion аոtiϲοаgսlаtion could not be exactly discerned in this trial but was deemed to be multifactorial, including presumed short-duration AF, perceived low thromboembolic risk, and lack of guideline adherence.<sup id="fnref:Pahng2024:3"><a href="#fn:Pahng2024" class="footnote" rel="footnote" role="doc-noteref">2</a></sup></p>
</blockquote>

<blockquote>
  <p>Though of unproven in efficacy, some of our contributors recommend аոtiϲοаgսlаtioո for four weeks after reversion to SR (either spontaneous or intended) for patients with AF of less than 48 hours duration, even for those with a low CHA2DS2-VASc score. The rationale for this approach is a concern regarding the high likelihood of ΑF recurrence in the first month after reversion to SR, as well as transient postcardioversion atrial stunning in the immediate pericardioversion period. This decision may be modified in patients at very high bleeding risk.<sup id="fnref:Pahng2024:4"><a href="#fn:Pahng2024" class="footnote" rel="footnote" role="doc-noteref">2</a></sup></p>
</blockquote>

<p>E em seguida diz:</p>

<blockquote>
  <p>Some of our contributors do not anticoagulate patients with a low CHA2DS2-VASc score (0 in men or 1 in women) after restoration of SR if ΑF was less than 48 hours duration.</p>
</blockquote>

<p>Ou seja, na prática cada cardiologista tem sua conduta individualizada. É algo dificil de determinar porque o risco existe e a decisão de anticoagular depende da percepção de cada médico de o quanto esse risco (um valor numérico) é aceitável ou não. Para alguns um risco de 0,2% de fazer um AVC/AIT pode ser baixo e para outros pode ser alto, considerando a grande morbidade num paciente jovem e previamente hígido.</p>

<p>O que diz a nova diretriz de FA da ESC de 2024:</p>

<blockquote>
  <p>Any rhythm control procedure has an inherent risk of thrombo­embolism. Patients undergoing cardioversion require at least 3 weeks of therapeutic anticoagulation (adherence to DOACs or INR &gt;2 if VKA) prior to the electrical or pharmacological procedure. In acute set­tings or when early cardioversion is needed, transoesophageal echocar­diography (TOE) can be performed to exclude cardiac thrombus prior to cardioversion. These approaches have been tested in multiple RCTs. In the case of thrombus detection, therapeutic anticoagu­lation should be instituted for a minimum of 4 weeks followed by repeat TOE to ensure thrombus resolution. When the definite duration of AF
is less than 48 hours, cardioversion has typically been considered with­out the need for pre-procedure OAC or TOE for thrombus exclusion. However, the ‘definite’ onset of AF is often not known, and observa­tional data suggest that stroke/thromboembolism risk is lowest within a much shorter time period. This task force reached consensus that safety should come first. <strong>Cardioversion is not recommended if AF duration is longer than 24 hours, unless the patient has already received at least 3 weeks of therapeutic anticoagulation or a TOE is performed</strong> to exclude intracardiac thrombus. Most patients should <strong>continue OAC for at least 4 weeks post-cardioversion</strong>. Only for those <strong>without thromboembolic risk</strong> factors and <strong>sinus rhythm restoration within 24h of AF onset</strong> is post-cardioversion OAC optional. In the presence of any thromboembolic risk factors, long-term OAC should be instituted irrespective of the rhythm outcome.<sup id="fnref:Garg2016:1"><a href="#fn:Garg2016" class="footnote" rel="footnote" role="doc-noteref">1</a></sup></p>
</blockquote>

<p>Resumindo a recomendação da ESC:</p>

<ol>
  <li>A anticoatulação <strong>pré-cardioversão</strong> pode ser dispensada se o início foi definitivamente há menos de 24 horas.</li>
  <li>A anticoagulação <strong>pós-cardioversão</strong> pode ser dispensada se o ritmo sinusal foi atingido com menor de 24 horas de duração fibrilação atrial <em>E</em> o paciente possui baixo risco tromboembólico.</li>
</ol>

<h2 id="referências">Referências</h2>

<div class="footnotes" role="doc-endnotes">
  <ol>
    <li id="fn:Garg2016">
      <p>Garg A, Khunger M, Seicean S, Chung MK, Tchou PJ. Incidence of Thromboembolic Complications Within 30 Days of Electrical Cardioversion Performed Within 48 Hours of Atrial Fibrillation Onset. JACC Clin Electrophysiol. 2016;2(4):487-494. doi:10.1016/j.jacep.2016.01.018 <a href="#fnref:Garg2016" class="reversefootnote" role="doc-backlink">&#8617;</a> <a href="#fnref:Garg2016:1" class="reversefootnote" role="doc-backlink">&#8617;<sup>2</sup></a></p>
    </li>
    <li id="fn:Pahng2024">
      <p>Phang R, Manning WJ. Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation. In: UpToDate. Disponível em: https://www.uptodate.com/contents/prevention-of-embolization-prior-to-and-after-restoration-of-sinus-rhythm-in-atrial-fibrillation. Acesso em 26 de dezembro de 2024 <a href="#fnref:Pahng2024" class="reversefootnote" role="doc-backlink">&#8617;</a> <a href="#fnref:Pahng2024:1" class="reversefootnote" role="doc-backlink">&#8617;<sup>2</sup></a> <a href="#fnref:Pahng2024:2" class="reversefootnote" role="doc-backlink">&#8617;<sup>3</sup></a> <a href="#fnref:Pahng2024:3" class="reversefootnote" role="doc-backlink">&#8617;<sup>4</sup></a> <a href="#fnref:Pahng2024:4" class="reversefootnote" role="doc-backlink">&#8617;<sup>5</sup></a></p>
    </li>
  </ol>
</div>

    <br/>
    <hr/>
    <span xmlns:cc="http://creativecommons.org/ns#" xmlns:dct="http://purl.org/dc/terms/">mosca.me &copy; 2025-2999
    <a href="https://creativecommons.org/licenses/by-sa/4.0/?ref=chooser-v1" target="_blank"
    rel="license noopener noreferrer" style="display:inline-block;">CC BY-SA 4.0</a></span><br />
    </span>
  </body>
</html>
